These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 12827718)

  • 1. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer screening in a rural population of Zimbabwe.
    Thistle PJ; Chirenje ZM
    Cent Afr J Med; 1997 Sep; 43(9):246-51. PubMed ID: 9509642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
    Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
    J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
    Sepúlveda C; Prado R
    Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pap smear screening in a health maintenance organization: 1986-1990.
    Rolnick S; LaFerla JJ; Wehrle D; Trygstad E; Okagaki T
    Prev Med; 1996; 25(2):156-61. PubMed ID: 8860280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance in cervical screening of a high risk population: a study of 65,753 reviewed cases in Parana Screening Program, Brazil.
    Collaço LM; de Noronha L; Pinheiro DL; Bleggi-Torres LF
    Diagn Cytopathol; 2005 Dec; 33(6):441-8. PubMed ID: 16299748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the feasibility of single lifetime PAP smear evaluation between 41-50 years of age as strategy for cervical cancer control in developing countries from our 32 years of experience of hospital-based routine cytological screening.
    Misra JS; Gupta HP; Das V
    Diagn Cytopathol; 2004 Dec; 31(6):376-9. PubMed ID: 15540174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML; Berger BM; Farber FL
    Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why women still die from cervical cancer.
    Masood S
    J Fla Med Assoc; 1997; 84(6):379-83. PubMed ID: 9379163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
    Perovic S
    J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
    Nygård M; Daltveit AK; Thoresen SO; Nygård JF
    BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing women's participation in Pap smear screening in Australia--how can we tell if the national policy is effective?
    Shelley J; Street A
    Aust Health Rev; 1992; 15(2):190-9. PubMed ID: 10119050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1994 Jul; 43(29):530-4. PubMed ID: 8028574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina.
    Arrossi S; Ramos S; Paolino M; Sankaranarayanan R
    Reprod Health Matters; 2008 Nov; 16(32):50-8. PubMed ID: 19027622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.